Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Cardiovascular events
[105] RCT	5926 people with vascular disease who were intolerant to ACE inhibitors	Cardiovascular mortality, MI, stroke, or hospital admission for heart failure 465/2954 (16%) with telmisartan 504/2972 (17%) with placebo	HR 0.92 95% CI 0.81 to 1.05 P = 0.22		Not significant
[105] RCT	5926 people with vascular disease who were intolerent to ACE inhibitors	Cardiovascular mortality, MI, or stroke 384/2954 (13%) with telmisartan 440/2972 (15%) with placebo	HR 0.86 95% CI 0.76 to 1.00 P = 0.045	Small effect size	telmisartan
[106] RCT	20,332 people with previous stroke and risk factors for vascular disease	Cardiovascular mortality, MI, stroke, or worsening or new heart failure 1367/10,146 (13.5%) with telmisartan 1463/10,186 (14.4%) with placebo	HR 0.94 95% CI 0.87 to 1.01		Not significant
[106] RCT	20,332 people with previous stroke and risk factors for vascular disease	Cardiovascular mortality, MI, stroke, or worsening or new heart failure within 6 months of randomisation 474/10,146 (5%) with telmisartan 433/10,986 (4%) with placebo	HR 1.10 95% CI 0.97 to 1.26		Not significant
[106] RCT	20,332 people with previous stroke and risk factors for vascular disease	Cardiovascular mortality, MI, stroke, or worsening or new heart failure >6 months after randomisation 893/10,146 (9%) with telmisartan 1030/10,186 (10%) with placebo	HR 0.87 95% CI 0.80 to 0.95	Small effect size	telmisartan
[105] RCT	26,258 people with vascular disease 2 RCTs in this analysis	Cardiovascular mortality, MI, stroke, or hospital admission for heart failure 1832/13,100 (14%) with telmisartan 1967/13,158 (15%) with placebo	OR 0.93 95% CI 0.86 to 0.99 P = 0.03	Small effect size	telmisartan
[105] RCT	26,258 people with vascular disease 2 RCTs in this analysis	Cardiovascular mortality, MI, stroke, or hospital admission for heart failure within 6 months of randomisation 546/13,100 (4.2%) with telmisartan 492/13,158 (3.7%) with placebo	OR 1.12 95% CI 0.99 to 1.27 P = 0.075		Not significant
[105] RCT	26,258 people with vascular disease	Cardiovascular mortality, MI, stroke, or hospital admission for heart failure >6 months after randomisation 1286/12,484 (10%) with telmisartan 1475/12,575 (12%) with placebo	OR 0.86 95% CI 0.80 to 0.94 P <0.001	Small effect size	telmisartan